Who are DIGOXIN's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lanoxin, Cinobufacini Injection, Rate-control therapy, Digoxin (0.25mg), Intra-amniotic injection of DIGOXIN, Magnesium sulfate and then Digoxin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chembl-chembl1751.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

DIGOXIN — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DIGOXIN (DIGOXIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cardiac Glycoside [EPC].

marketed Cardiac Glycoside [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

DIGOXIN (DIGOXIN).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DIGOXIN TARGET	DIGOXIN		marketed	Cardiac Glycoside [EPC]		1975-01-01
Lanoxin	digoxin	Generic (originally Burroughs Wellcome/GSK)	marketed	Cardiac Glycoside [EPC]	Nuclear receptor ROR-gamma, Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2	1954-01-01
Cinobufacini Injection	Cinobufacini Injection	Dongfang Hospital Beijing University of Chinese Medicine	marketed	Natural product bufadienolide; cardiac glycoside analog	Na+/K+-ATPase; multiple apoptotic pathways
Rate-control therapy	Rate-control therapy	Our Lady of the Lake Hospital	marketed	AV nodal blocking agents (beta-blockers, non-dihydropyridine calcium channel blockers, or cardiac glycosides)	AV nodal conduction (multiple targets depending on agent: beta-1 adrenergic receptors, L-type calcium channels, or adenosine receptors)
Digoxin (0.25mg)	Digoxin (0.25mg)	Advenchen Laboratories, LLC	phase 3	Cardiac glycoside	Na+/K+-ATPase
Intra-amniotic injection of DIGOXIN	Intra-amniotic injection of DIGOXIN	Meir Medical Center	phase 3	Cardiac glycoside	Na+/K+-ATPase
Magnesium sulfate and then Digoxin	Magnesium sulfate and then Digoxin	Sunnybrook Health Sciences Centre	phase 3	Electrolyte supplement and cardiac glycoside combination	Na+/K+-ATPase (digoxin); magnesium-dependent ion channels and enzymes (magnesium sulfate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cardiac Glycoside [EPC] class)

· 1 drug in this class
Generic (originally Burroughs Wellcome/GSK) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DIGOXIN — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl1751. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab